Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (241-250 of 337) with videos related to

Pageof 34
Sort By:
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pageof 34

Showing results (241-250 of 337) with videos related to

Sort By:
Pageof 34
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pageof 34